단클론항체 시장 보고서 : 생산 방법, 공급원, 적응증, 최종 용도, 지역별(2024-2032년)

The global monoclonal antibodies market size reached US$ 221.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 392.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032.

Monoclonal antibodies (mAbs) are laboratory-produced proteins used to serve as substitute antibodies that can enhance, modify, restore, and mimic the attack of the immune system on unwanted cells. They are utilized for detecting and targetting cancer cells for destruction by enhancing the immune system. They are also employed to block the connection between a cancer cell and proteins that promote cell growth. In addition, they prevent the formation of proteins for enabling immune system cells to work efficiently against cancer cells. Besides this, mAbs transport the radiation treatment directly to cancer cells and minimize the effect of radiation on healthy cells

Monoclonal Antibodies Market Trends:

At present, the growing prevalence of chronic diseases, such as cancer, heart disease, stroke, diabetes, and arthritis, represents one of the key factors driving the market. Besides this, leading manufacturers are extensively investing in research and development (R&D) activities to introduce enhanced mAb drugs for treating neurodegenerative diseases, such as Alzheimer's, Huntington's, Parkinson's, and Lewy body diseases. They are also focusing on various marketing strategies to expand their customer base, which is contributing to the growth of the market. In addition, the increasing demand for humanized mAbs to treat various antigens, such as cancer cells, immunosuppression, and immunomodulatory molecules, are offering lucrative growth opportunities to industry investors. Apart from this, there is a rise in the demand for cost-efficient biosimilar mAbs to treat cancer across the globe. This, along with the burgeoning healthcare industry, is propelling the growth of the market. Moreover, technological advancements in various genetic platforms, such as next-generation sequencing, is offering a positive market outlook. Additionally, there is an increase in the employment of advanced genetic engineering technology in mAbs production around the world. This, coupled with the rising awareness among the masses about the benefits of mAb therapy, is bolstering the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on production method, source, indication and end use.

Breakup by Production Method:

In Vivo

In Vitro

Breakup by Source:

Murine

Chimeric

Humanized

Human

Breakup by Indication:

Cancer

Autoimmune Diseases

Inflammatory Diseases

Infectious Diseases

Others

Breakup by End Use:

Hospitals

Research Institutes

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., Biogen Inc., F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1. What was the size of the global monoclonal antibodies market in 2023?
• 2. What is the expected growth rate of the global monoclonal antibodies market during 2024-2032?
• 3. What are the key factors driving the global monoclonal antibodies market?
• 4. What has been the impact of COVID-19 on the global monoclonal antibodies market?
• 5. What is the breakup of the global monoclonal antibodies market based on the production method?
• 6. What is the breakup of the global monoclonal antibodies market based on the source?
• 7. What is the breakup of the global monoclonal antibodies market based on the indication?
• 8. What is the breakup of the global monoclonal antibodies market based on the end use?
• 9. What are the key regions in the global monoclonal antibodies market?
• 10. Who are the key players/companies in the global monoclonal antibodies market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Monoclonal Antibodies Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Production Method

• 6.1 In Vivo
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 In Vitro
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Source

• 7.1 Murine
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Chimeric
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Humanized
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Human
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Indication

• 8.1 Cancer
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Autoimmune Diseases
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Inflammatory Diseases
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Infectious Diseases
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by End Use

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Research Institutes
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 AbbVie Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Amgen Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Biogen Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 F. Hoffmann-La Roche AG
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
  • 15.3.5 GSK plc
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Johnson & Johnson
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Merck KGaA
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Novartis AG
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Novo Nordisk A/S
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Pfizer Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Sanofi S.A.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Thermo Fisher Scientific Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis